Cresco Labs (CL) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue reached $166 million, with strong brand performance and retail productivity offsetting price compression.

• Focused on generating cash, disciplined capital allocation, and strengthening the balance sheet, prioritizing long-term value.

• Maintained #1 market share in several billion-dollar cannabis markets and operated 72 retail stores.

• Ended the quarter with $162 million in cash, the highest balance in three years.

• Strategic pillars include optimizing profitability, leading in branded wholesale, and building a productive retail platform.

Financial highlights

• Q1 2025 adjusted gross profit was $82 million (49% margin); adjusted EBITDA was $36 million (22% margin); net loss was $15 million.

• Revenue declined from $184.3 million in Q1 2024 to $166 million in Q1 2025.

• Free cash flow for Q1 2025 was $24.7 million; operating cash flow was $30 million.

• Adjusted SG&A reduced to $53 million; SG&A expenses were $58 million, or 35% of revenue.

• Receivables reduced by up to 15% since end of 2024.

Outlook and guidance

• Q2 revenue expected to be down slightly due to Illinois' mandatory seed-to-sale system conversion, with normalization anticipated in future quarters.

• Margin pressure expected in Q2, with a couple hundred basis point impact, and modest margin pressure for the remainder of the year.

• Strategic priorities include maximizing core and new market opportunities, expanding retail network and efficiency, and entering new growth platforms.

• Management emphasized maintaining financial flexibility and a strong balance sheet to support long-term value creation and margin expansion.

• Committed to profitable sales that convert to cash, rather than chasing topline revenue.